{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:54Z","timestamp":1792511934924,"version":"4.5.0"},"reference-count":48,"publisher":"BMJ","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2022,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To study the association between covid-19 vaccines, SARS-CoV-2 infection, and risk of immune mediated neurological events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Population based historical rate comparison study and self-controlled case series analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Primary care records from the United Kingdom, and primary care records from Spain linked to hospital data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>8\u2009330\u2009497 people who received at least one dose of covid-19 vaccines ChAdOx1 nCoV-19, BNT162b2, mRNA-1273, or Ad.26.COV2.S between the rollout of the vaccination campaigns and end of data availability (UK: 9 May 2021; Spain: 30 June 2021). The study sample also comprised a cohort of 735\u2009870 unvaccinated individuals with a first positive reverse transcription polymerase chain reaction test result for SARS-CoV-2 from 1 September 2020, and 14\u2009330\u2009080 participants from the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Outcomes were incidence of Bell\u2019s palsy, encephalomyelitis, Guillain-Barr\u00e9 syndrome, and transverse myelitis. Incidence rates were estimated in the 21 days after the first vaccine dose, 90 days after a positive test result for SARS-CoV-2, and between 2017 and 2019 for background rates in the general population cohort. Indirectly standardised incidence ratios were estimated. Adjusted incidence rate ratios were estimated from the self-controlled case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 4\u2009376\u2009535 people who received ChAdOx1 nCoV-19, 3\u2009588\u2009318 who received BNT162b2, 244\u2009913 who received mRNA-1273, and 120\u2009731 who received Ad26.CoV.2; 735\u2009870 people with SARS-CoV-2 infection; and 14\u2009330\u2009080 people from the general population. Overall, post-vaccine rates were consistent with expected (background) rates for Bell\u2019s palsy, encephalomyelitis, and Guillain-Barr\u00e9 syndrome. Self-controlled case series was conducted only for Bell\u2019s palsy, given limited statistical power, but with no safety signal seen for those vaccinated. Rates were, however, higher than expected after SARS-CoV-2 infection. For example, in the data from the UK, the standardised incidence ratio for Bell\u2019s palsy was 1.33 (1.02 to 1.74), for encephalomyelitis was 6.89 (3.82 to 12.44), and for Guillain-Barr\u00e9 syndrome was 3.53 (1.83 to 6.77). Transverse myelitis was rare (&lt;5 events in all vaccinated cohorts) and could not be analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No safety signal was observed between covid-19 vaccines and the immune mediated neurological events of Bell\u2019s palsy, encephalomyelitis, Guillain-Barr\u00e9 syndrome, and transverse myelitis. An increased risk of Bell\u2019s palsy, encephalomyelitis, and Guillain-Barr\u00e9 syndrome was, however, observed for people with SARS-CoV-2 infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmj-2021-068373","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T20:10:57Z","timestamp":1647461457000},"page":"e068373","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":103,"title":["Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis"],"prefix":"10.1136","volume":"376","author":[{"given":"Xintong","family":"Li","sequence":"first","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Ravent\u00f3s","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Universitari per a la recerca a l\u2019Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain"},{"name":"Universitat Aut\u00f2noma de Barcelona, Bellaterra (Cerdanyola del Vall\u00e8s), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Roel","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Universitari per a la recerca a l\u2019Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain"},{"name":"Universitat Aut\u00f2noma de Barcelona, Bellaterra (Cerdanyola del Vall\u00e8s), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pistillo","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Universitari per a la recerca a l\u2019Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Martinez-Hernandez","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Clinic de Barcelona and University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Delmestri","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlen","family":"Reyes","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Universitari per a la recerca a l\u2019Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Strauss","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-6346","authenticated-orcid":false,"given":"Daniel","family":"Prieto-Alhambra","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford OX3 7LD, UK"},{"name":"Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Burn","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford OX3 7LD, UK"},{"name":"Fundaci\u00f3 Institut Universitari per a la recerca a l\u2019Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita","family":"Duarte-Salles","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Universitari per a la recerca a l\u2019Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"2025110101460777000_376.mar16_9.e068373.1","unstructured":"WHO. COVID-19 Dashboard. Geneva: World Health Organization, 2020. https:\/\/covid19.who.int (accessed 14 January 2022)."},{"key":"2025110101460777000_376.mar16_9.e068373.2","unstructured":"European Medicines Agency. COVID-19 vaccines: authorised. www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/vaccines-covid-19\/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section (accessed 14 January 2022)."},{"key":"2025110101460777000_376.mar16_9.e068373.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2025110101460777000_376.mar16_9.e068373.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2025110101460777000_376.mar16_9.e068373.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"2025110101460777000_376.mar16_9.e068373.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544"},{"key":"2025110101460777000_376.mar16_9.e068373.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659"},{"key":"2025110101460777000_376.mar16_9.e068373.8","unstructured":"European Medicines Agency. COVID-19 Vaccine Janssen: Guillain-Barr\u00e9 syndrome listed as a very rare side effect. www.ema.europa.eu\/en\/news\/covid-19-vaccine-janssen-guillain-barre-syndrome-listed-very-rare-side-effect (accessed 19 October 2021)."},{"key":"2025110101460777000_376.mar16_9.e068373.9","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4756"},{"key":"2025110101460777000_376.mar16_9.e068373.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102540"},{"key":"2025110101460777000_376.mar16_9.e068373.11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13426"},{"key":"2025110101460777000_376.mar16_9.e068373.12","doi-asserted-by":"publisher","DOI":"10.1002\/lt.26279"},{"key":"2025110101460777000_376.mar16_9.e068373.13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26065"},{"key":"2025110101460777000_376.mar16_9.e068373.14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653786"},{"key":"2025110101460777000_376.mar16_9.e068373.15","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcab143"},{"key":"2025110101460777000_376.mar16_9.e068373.16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26182"},{"key":"2025110101460777000_376.mar16_9.e068373.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106839"},{"key":"2025110101460777000_376.mar16_9.e068373.18","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2025110101460777000_376.mar16_9.e068373.19","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025110101460777000_376.mar16_9.e068373.20","doi-asserted-by":"publisher","DOI":"10.48329\/PYC2-WE97"},{"key":"2025110101460777000_376.mar16_9.e068373.21","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.23.21266734"},{"key":"2025110101460777000_376.mar16_9.e068373.22","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1726481"},{"key":"2025110101460777000_376.mar16_9.e068373.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1435"},{"key":"2025110101460777000_376.mar16_9.e068373.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4515"},{"key":"2025110101460777000_376.mar16_9.e068373.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9179"},{"key":"2025110101460777000_376.mar16_9.e068373.26","doi-asserted-by":"publisher","DOI":"10.2307\/2982934"},{"key":"2025110101460777000_376.mar16_9.e068373.27","doi-asserted-by":"publisher","DOI":"10.1145\/2414416.2414791"},{"key":"2025110101460777000_376.mar16_9.e068373.28","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2477"},{"key":"2025110101460777000_376.mar16_9.e068373.29","unstructured":"bc-coordinator. Priority list of adverse events of special interest: COVID-19. 2020. https:\/\/brightoncollaboration.us\/priority-list-aesi-covid\/ (accessed 11 Mar 2021)."},{"key":"2025110101460777000_376.mar16_9.e068373.30","unstructured":"Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology. CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol. www.bestinitiative.org\/wp-content\/uploads\/2021\/02\/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf (accessed 11 Mar 2021)."},{"key":"2025110101460777000_376.mar16_9.e068373.31","unstructured":"Food and Drug Administration. Briefing Document. Pfizer-BioNTech COVID-19 Vaccine. In: Vaccines and Related Biological Products Advisory Committee Meeting. www.fda.gov\/media\/144245\/download (accessed 15 September 2021)"},{"key":"2025110101460777000_376.mar16_9.e068373.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32623-4"},{"key":"2025110101460777000_376.mar16_9.e068373.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201"},{"key":"2025110101460777000_376.mar16_9.e068373.34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011881"},{"key":"2025110101460777000_376.mar16_9.e068373.35","unstructured":"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults. NCT04516746. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04516746 [cited 2021 Apr 1]"},{"key":"2025110101460777000_376.mar16_9.e068373.36","unstructured":"Food and Drug Administration. Briefing Document. Moderna COVID-19 Vaccine. In: Vaccines and Related Biological Products Advisory Committee Meeting. www.fda.gov\/media\/144434\/download"},{"key":"2025110101460777000_376.mar16_9.e068373.37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15072"},{"key":"2025110101460777000_376.mar16_9.e068373.38","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.2219"},{"key":"2025110101460777000_376.mar16_9.e068373.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.08.071"},{"key":"2025110101460777000_376.mar16_9.e068373.40","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00451-5"},{"key":"2025110101460777000_376.mar16_9.e068373.41","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.21.21265314"},{"key":"2025110101460777000_376.mar16_9.e068373.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01556-7"},{"key":"2025110101460777000_376.mar16_9.e068373.43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.16496"},{"key":"2025110101460777000_376.mar16_9.e068373.44","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa240"},{"key":"2025110101460777000_376.mar16_9.e068373.45","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(20)30287-X"},{"key":"2025110101460777000_376.mar16_9.e068373.46","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn310"},{"key":"2025110101460777000_376.mar16_9.e068373.47","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309056"},{"key":"2025110101460777000_376.mar16_9.e068373.48","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-021-04959-6"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2021-068373","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2021-068373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:46:16Z","timestamp":1761986776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2021-068373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":48,"alternative-id":["10.1136\/bmj-2021-068373"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2021-068373","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.08.21263276","asserted-by":"object"}]},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]}}}